PCSK9 and homozygous familial hypercholesterolemia: Noteworthy among them are ezetimibe, targeting intestinal cholesterol absorption and often used in combination with statins; mipomersen and lomitapide, prescribed to reduce LDL-C in patients with HoFH; and evolocumab and alirocumab, potent PCSK9 inhibitors exerting a significant impact on cholesterol levels, which is integral in secondary therapies when statins prove insufficient.